Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$42.18 USD

42.18
890,330

+1.07 (2.60%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $42.20 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

AnaptysBio (ANAB) Jumps: Stock Rises 7.7%

AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

IVERIC bio (ISEE) Catches Eye: Stock Jumps 6.8%

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session

NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus

Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.

Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session

Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands

Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

Bruker Rides on Nano and MALDI Launches Despite Margin Debacle

Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.

Abbott's Data From Interim Clinical Study of ID NOW Positive

Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.

Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?

Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.

Evelo Biosciences (EVLO) Looks Good: Stock Adds 5.9% in Session

Evelo Biosciences (EVLO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session

Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

NuVasive's (NUVA) MaXcess Retractor Study Results Positive

NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.

Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?

Is (QGEN) Outperforming Other Medical Stocks This Year?

Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio

Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.

Verastem (VSTM) Jumps: Stock Rises 7.1%

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Walgreens' Pharmacy International Arm Faces Coronavirus Woes

Walgreens (WBA) expects the adverse impact of COVID-19 to continue in the fiscal fourth quarter.

Integra (IART) Preliminary Q3 Results Show Recovery in Sales

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now

Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing

The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.

Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries

Zacks.com featured highlights include: Stamps, QIAGEN, Owens & Minor, Flowers Foods and Lakeland Industries

Urmimala Biswas headshot

Coronavirus Drives Testing Stocks: Is There Room for More Upside?

Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.

Here's Why You Should Add Globus Medical to Your Portfolio

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.

Urmimala Biswas headshot

LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA

According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.